SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Energy Biosystem Corp NASDAQ-ENBC

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sector Investor who wrote (332)5/23/2000 9:18:00 AM
From: Sector Investor  Read Replies (1) of 336
 
News II:

Genencor International Signs Licensing Agreement With Energy Biosystems for Gene Shuffling Technology

PALO ALTO, Calif. and ROCHESTER, NY--(BUSINESS WIRE)--May 23, 2000--Genencor International, Inc. today announced it has entered into a licensing agreement with Energy Biosystems Corporation (NASDAQ: ENBC) of The Woodlands, Texas, for use of the company's proprietary gene shuffling technology for development of gene-based products
for the cleaning, textiles, grain processing, animal feed and food ingredients industries.

The licensing agreement represents the first in a series of expected agreements between the two companies that will cover research and development, as well as options to expand the licensed rights into the fields of agricultural and biomaterial products.

Genencor International develops genetically based biotechnology products for industrial chemicals, agriculture, and health care markets. The company has principal corporate offices in Palo Alto, Calif., Rochester, N.Y. and Leiden, the Netherlands.

Energy BioSystems Corporation, of The Woodlands, Texas, is a biotechnology company that is applying proprietary, directed evolution techniques to accelerate development and
commercialization of biocataylst-based processes for petroleum refining and petrochemicals production, industrial enzyme, ag-bio, chemical and pharmaceutical markets.

Contact:

Genencor International
Amy Giller, 650/846-7500 (Investors)
Angie Blackwell, 716/256-5200 (Media)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext